Life-threatening complications of adult-onset Still's disease

被引:124
作者
Efthimiou, Petros [1 ,2 ]
Kadavath, Sabeeda [1 ]
Mehta, Bella [3 ]
机构
[1] Lincoln Med & Mental Hlth Ctr, Div Rheumatol, New York, NY 10451 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Westchester Med Ctr, New York, NY USA
关键词
Adult-onset still's disease; Complications; Etiology; Macrophage activation syndrome (MAS); Pathogenesis; Treatment; MACROPHAGE ACTIVATION SYNDROME; THROMBOTIC THROMBOCYTOPENIC PURPURA; PULMONARY ARTERIAL-HYPERTENSION; JUVENILE IDIOPATHIC ARTHRITIS; CONNECTIVE-TISSUE DISEASE; HEMOLYTIC-UREMIC SYNDROME; CLINICAL-MANIFESTATIONS; HEMOPHAGOCYTIC SYNDROME; PLASMA-EXCHANGE; ANAKINRA;
D O I
10.1007/s10067-014-2487-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adult-onset Still's Disease (AOSD) since its description in 1971 has proven to be a very complex and challenging disease entity. This rare auto-inflammatory disease is classically described by the "Still's triad" of fever, rash, and arthritis, although the atypical cases frequently outnumber the typical ones. The exact pathogenesis and etiologic factors responsible for the clinical features remain largely obscure, despite recent suggestive cytokine biology findings. Diagnosis is made on clinical grounds, following the exclusion of mimickers of infectious, autoimmune or neoplastic etiology, with the additional consideration of non-specific laboratory abnormalities such as peripheral leukocytosis and elevation of serum ferritin and other acute phase reactants. The disease manifestations are protean and can include diverse complications, affecting multiple organ systems. Moreover, the severity of the organ involvement can vary considerably, representing a wide spectrum from the self-limited to severe. The mainstay of therapy has evolved from the traditional use of corticosteroids and oral immunosupressants to the newer targeted treatments with biologic agents. The scope of this review is to alert the clinician to the existence of life-threatening AOSD complications, namely the macrophage activation syndrome, disseminated intravascular coagulopathy, thrombotic thrombocytopenic purpura, diffuse alveolar hemorrhage, and pulmonary arterial hypertension. Such knowledge may lead in earlier recognition, prompt treatment, and, ideally, improved patient outcomes.
引用
收藏
页码:305 / 314
页数:10
相关论文
共 109 条
[1]  
Aellen P, 1991, Schweiz Rundsch Med Prax, V80, P376
[2]   Successful treatment of refractory adult onset Still's disease with rituximab [J].
Ahmadi-Simab, K. ;
Lamprecht, P. ;
Jankowiak, C. ;
Gross, W. L. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (08) :1117-1118
[3]  
Aikawa NE, 2009, ISR MED ASSOC J, V11, P635
[4]   INTERLEUKIN-6 IN BIOLOGY AND MEDICINE [J].
AKIRA, S ;
TAGA, T ;
KISHIMOTO, T .
ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 :1-78
[5]  
Andrés E, 2003, HEPATO-GASTROENTEROL, V50, P192
[6]  
Arai Yukihiro, 2004, Rinsho Ketsueki, V45, P316
[7]   Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature [J].
Arlet, J.-B. ;
Huong, D. Le Thi ;
Marinho, A. ;
Amoura, Z. ;
Wechsler, B. ;
Papo, T. ;
Piette, J-C .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) :1596-1601
[8]  
ARLET JB, 2006, ANN RHEUM DIS
[9]  
Badesch DB, 2007, J RHEUMATOL, V34, P2417
[10]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+